Indication
HIV-associated Tuberculosis
1 clinical trial
4 products
Clinical trial
Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated TuberculosisStatus: Recruiting, Estimated PCD: 2025-02-28
Product
DolutegravirProduct
DTGProduct
2HPZMProduct
2HPM